VESLETEPLIRSEN(SRP-5051) clinical trials

A Phase 2, Two-Part, Multiple-Ascending-Dose Study of SRP-5051 for Dose Determination, then Dose Expansion, in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51-Skipping Treatment

This study is testing a new medicine called VESLETEPLIRSEN for Duchenne muscular dystrophy in males over 18. It aims to find the best dose and check how safe it is, while also measuring its effect on a muscle protein called dystrophin.